Provided by Tiger Fintech (Singapore) Pte. Ltd.

PTC Therapeutics

47.39
+0.98002.11%
Post-market: 47.390.00000.00%18:31 EDT
Volume:1.04M
Turnover:48.92M
Market Cap:3.74B
PE:-10.02
High:47.96
Open:46.33
Low:45.95
Close:46.41
Loading ...

PTC Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
01 Mar

Q4 2024 PTC Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
01 Mar

Stock Track | PTC Therapeutics Soars 5.28% Pre-Market on Strong Earnings, Promising Pipeline Updates and Bullish Analyst Views

Stock Track
·
28 Feb

Stock Track | PTC Therapeutics Plummets 11.43% as JPMorgan Cuts Price Target

Stock Track
·
28 Feb

RBC Capital Adjusts PTC Therapeutics Price Target to $64 From $63, Maintains Outperform Rating

MT Newswires Live
·
28 Feb

PTC Therapeutics: Buy Rating Backed by Promising Clinical Catalysts and Solid Commercial Foundation

TIPRANKS
·
28 Feb

PTC Therapeutics price target lowered to $72 from $74 at JPMorgan

TIPRANKS
·
28 Feb

PTC Therapeutics: Strong Financial Performance and Strategic Partnerships Justify Buy Rating

TIPRANKS
·
28 Feb

PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

GuruFocus.com
·
28 Feb

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
28 Feb

PTC Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

PTC Therapeutics Exceeds 2024 Revenue Guidance

TIPRANKS
·
28 Feb

PTC Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
28 Feb

PTC Therapeutics Q4 2024 Adj EPS $(0.85) Misses $(0.66) Estimate, Sales $213.00M Miss $232.44M Estimate

Benzinga
·
28 Feb

PTC Therapeutics Q4 Product Revenue USD 154.706 Million

THOMSON REUTERS
·
28 Feb

PTC Therapeutics Inc Outlook 2025 Total REV Between $600 Mln and $800 Mln

THOMSON REUTERS
·
28 Feb

Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Zacks
·
24 Feb

Hold Rating on PTC Therapeutics Amidst Mixed Outcomes for Vatiquinone in Friedreich’s Ataxia Treatment

TIPRANKS
·
19 Feb

PTC Therapeutics Says FDA Grants Priority Review to Vatiquinone NDA for Treating Friedreich's Ataxia; Shares Up Pre-Bell

MT Newswires Live
·
19 Feb

BRIEF-Ptc Therapeutics Announces FDA Acceptance And Priority Review For Vatiquinone NDA

Reuters
·
19 Feb